VXRT - Vaxart's COVID-19 vaccine candidates show positive data in preclinical study

Vaxart (NASDAQ:VXRT) on Friday reported positive preliminary preclinical data that showed two of its COVID-19 vaccine candidates targeting either the SARS-CoV-2 spike (S) protein for Wuhan or S protein for Omicron protected hamsters when challenged with the Omicron BA.1 variant. The company developed an Omicron specific vaccine candidate and compared it with its original vaccine candidate that is currently in Phase II trials. Both vaccines produced antibody responses to the S protein of Omicron, with the Omicron candidate slightly better at making serum IgG antibodies to the matched protein. On Thursday, the company reported positive preliminary data from its phase 1b trial of its oral norovirus vaccine candidate in adults aged 55-80 years.

For further details see:

Vaxart’s COVID-19 vaccine candidates show positive data in preclinical study